Hybio Pharmaceutical Co., Ltd. (300199.SZ)
CNY 13.0
(4.17%)
CNY 13.0
(4.17%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 1.66 Billion CNY | -1.56% |
| 2022 | 1.69 Billion CNY | 2.73% |
| 2021 | 1.64 Billion CNY | 10.21% |
| 2020 | 1.49 Billion CNY | 23.89% |
| 2019 | 1.2 Billion CNY | 492.43% |
| 2018 | 203.57 Million CNY | 141.24% |
| 2017 | -493.61 Million CNY | -6.66% |
| 2016 | -462.79 Million CNY | -248.88% |
| 2015 | 310.84 Million CNY | 162.01% |
| 2014 | -501.29 Million CNY | -12.03% |
| 2013 | -447.48 Million CNY | 27.49% |
| 2012 | -617.09 Million CNY | 22.19% |
| 2011 | -793.12 Million CNY | -849.0% |
| 2010 | -83.57 Million CNY | -60.59% |
| 2009 | -52.04 Million CNY | -16.71% |
| 2008 | -44.58 Million CNY | -2413.51% |
| 2007 | -1.77 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q3 | 1.36 Billion CNY | -19.44% |
| 2024 Q1 | 1.65 Billion CNY | -0.32% |
| 2024 Q2 | 1.7 Billion CNY | 2.45% |
| 2023 Q2 | 1.65 Billion CNY | -4.27% |
| 2023 Q3 | 1.68 Billion CNY | 1.81% |
| 2023 FY | 1.66 Billion CNY | -1.56% |
| 2023 Q4 | 1.66 Billion CNY | -1.34% |
| 2023 Q1 | 1.73 Billion CNY | 2.37% |
| 2022 Q1 | 1.64 Billion CNY | 0.01% |
| 2022 Q4 | 1.69 Billion CNY | -2.5% |
| 2022 Q2 | 1.65 Billion CNY | 0.25% |
| 2022 FY | 1.69 Billion CNY | 2.73% |
| 2022 Q3 | 1.73 Billion CNY | 5.09% |
| 2021 Q3 | 1.58 Billion CNY | 3.33% |
| 2021 Q1 | 1.46 Billion CNY | -1.63% |
| 2021 Q2 | 1.53 Billion CNY | 4.49% |
| 2021 FY | 1.64 Billion CNY | 10.21% |
| 2021 Q4 | 1.64 Billion CNY | 3.76% |
| 2020 Q4 | 1.49 Billion CNY | 27.4% |
| 2020 FY | 1.49 Billion CNY | 23.89% |
| 2020 Q1 | 1.27 Billion CNY | 5.67% |
| 2020 Q2 | 1.28 Billion CNY | 1.06% |
| 2020 Q3 | 1.17 Billion CNY | -8.94% |
| 2019 FY | 1.2 Billion CNY | 492.43% |
| 2019 Q1 | 599.3 Million CNY | 194.39% |
| 2019 Q2 | 824.11 Million CNY | 37.51% |
| 2019 Q3 | 1.15 Billion CNY | 39.58% |
| 2019 Q4 | 1.2 Billion CNY | 4.85% |
| 2018 Q4 | 203.57 Million CNY | 261.94% |
| 2018 FY | 203.57 Million CNY | 141.24% |
| 2018 Q3 | -125.71 Million CNY | 12.28% |
| 2018 Q2 | -143.3 Million CNY | 71.97% |
| 2018 Q1 | -511.2 Million CNY | -3.56% |
| 2017 Q2 | -420.09 Million CNY | -5.18% |
| 2017 Q1 | -399.4 Million CNY | 13.7% |
| 2017 FY | -493.61 Million CNY | -6.66% |
| 2017 Q4 | -493.61 Million CNY | -19.51% |
| 2017 Q3 | -413.05 Million CNY | 1.68% |
| 2016 FY | -462.79 Million CNY | -248.88% |
| 2016 Q2 | 365.21 Million CNY | -15.44% |
| 2016 Q1 | 431.9 Million CNY | 38.94% |
| 2016 Q3 | -253.02 Million CNY | -169.28% |
| 2016 Q4 | -462.79 Million CNY | -82.91% |
| 2015 Q3 | 230.16 Million CNY | 35.52% |
| 2015 Q1 | -63.34 Million CNY | 87.36% |
| 2015 FY | 310.84 Million CNY | 162.01% |
| 2015 Q4 | 310.84 Million CNY | 35.06% |
| 2015 Q2 | 169.83 Million CNY | 368.11% |
| 2014 Q3 | -415.46 Million CNY | 5.14% |
| 2014 FY | -501.29 Million CNY | -12.03% |
| 2014 Q1 | -421.19 Million CNY | 5.88% |
| 2014 Q4 | -501.29 Million CNY | -20.66% |
| 2014 Q2 | -437.97 Million CNY | -3.98% |
| 2013 Q2 | -421.29 Million CNY | 12.14% |
| 2013 FY | -447.48 Million CNY | 27.49% |
| 2013 Q4 | -447.48 Million CNY | -9.06% |
| 2013 Q3 | -410.29 Million CNY | 2.61% |
| 2013 Q1 | -479.5 Million CNY | 22.3% |
| 2012 Q4 | -617.09 Million CNY | 1.23% |
| 2012 FY | -617.09 Million CNY | 22.19% |
| 2012 Q1 | -737.21 Million CNY | 7.05% |
| 2012 Q2 | -676.01 Million CNY | 8.3% |
| 2012 Q3 | -624.8 Million CNY | 7.58% |
| 2011 Q4 | -793.12 Million CNY | -1.61% |
| 2011 Q2 | -808.94 Million CNY | -0.1% |
| 2011 Q1 | -808.15 Million CNY | -866.98% |
| 2011 Q3 | -780.56 Million CNY | 3.51% |
| 2011 FY | -793.12 Million CNY | -849.0% |
| 2010 Q2 | -61.46 Million CNY | 0.0% |
| 2010 FY | -83.57 Million CNY | -60.59% |
| 2010 Q4 | -83.57 Million CNY | 0.0% |
| 2009 FY | -52.04 Million CNY | -16.71% |
| 2008 FY | -44.58 Million CNY | -2413.51% |
| 2007 FY | -1.77 Million CNY | 0.0% |